Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Sleep drug studied for breast cancer Survivors' insomnia

NCT ID NCT06162663

Symptom relief Sponsor: Medical University of South Carolina Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 2 times

Summary

This study tested whether the sleep medication suvorexant (20 mg) could help breast cancer survivors who have trouble sleeping. Participants were postmenopausal women taking hormone-blocking drugs. The study was stopped early after enrolling only 5 people, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

6 people

The number who actually took part.

Started

Sep 2024

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult post menopausal breast cancer survivors (female, \> 18 years old) * current selective estrogen modulator or aromatase inhibitor use * at least 6 weeks beyond completion of definitive treatment for breast cancer * less than 5 years from time of diagnosis. Exclusion Criteria: * less than 6-month life expectancy * current steroid use * severe depression or anxiety * severe hepatic impairment * concurrent use of moderate or strong CYP3A inhibitors * current receipt of hospice care * severe mental illness * current use of greater than 40 morphine milligram equivalents daily * diagnosis of obstructive sleep apnea, narcolepsy or other sleep related illness other than insomnia * pregnancy * treatment with alternate pharmacotherapy for insomnia at the time of trial initiation * menstrual cycle within the past year

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm insomnia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer Insomnia

Contacts and locations

Locations

  • MUSC Department of Family Medicine

    Charleston, South Carolina, 29425, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.